Skip to main content

Table 4 Treatment outcome by FCGR2A genotype, KRAS or BRAF mutational status, and therapy received

From: FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab

 

FLOX

FLOX + cetuximab

 

H/H

H/R

R/R

H/H

H/R

R/R

Interaction P-value

KRAS wild-type (N = 273)

Number of patients

N = 16

N = 52

N = 20

N = 46

N = 98

N = 41

 

Response

63% (10/16)

42% (22/52)

45% (9/20)

46% (21/46)

51% (50/98)

56% (23/41)

0.27*

PFS

8.4

8.9

9.0

7.7

7.7

8.0

0.23†

OS

31.6

23.6

19.0

21.4

20.7

18.9

0.23†

KRAS mutated (N = 169)

Number of patients

N = 10

N = 25

N = 21

N = 28

N = 57

N = 28

 

Response

60% (6/10)

52% (13/25)

19% (4/21)

36% (10/28)

46% (26/57)

50% (14/28)

0.04*

PFS

8.1

8.3

7.1

7.7

8.1

6.7

0.90†

OS

17.2

20.4

24.3

21.1

20.0

16.8

0.34†

BRAF wild-type (N = 363)

Number of patients

N = 22

N = 62

N = 34

N = 58

N = 130

N = 57

 

Response

64% (14/22)

48% (30/62)

35% (12/34)

47% (27/58)

52% (68/130)

54% (31/57)

0.10*

PFS

9.3

8.9

7.7

8.5

8.1

8.0

0.47†

OS

31.6

23.8

21.5

21.9

21.5

17.6

0.93†

BRAF mutated (N = 47)

Number of patients

N =3

N = 10

N = 4

N = 8

N = 16

N = 6

 

Response

33% (1/3)

20% (2/10)

0% (0/4)

13% (1/8)

25% (4/16)

33% (2/6)

0.72*

PFS

4.3

5.1

3.8

3.8

4.6

5.8

0.36†

OS

9.2

9.4

5.6

8.9

8.1

11.3

0.73†

  1. *Logistic regression, †Cox proportional hazard model.